The Center for Medical Technology Policy is launching an effort to create a “set of core outcomes for nonalcoholic steatohepatitis (NASH).”
“The goal is to conduct a rigorous multi-stakeholder consensus process to establish a minimal set of outcomes essential to collect in all late phase drug intervention studies for NASH,” CMTP President and CEO Sean Tunis said in a newsletter.
NASH affects roughly 15 million adults in the U.S., according to CMTP.
The project will reportedly be completed in nine to 12 months, CMPT says, to “assure the results are available in a timely fashion to innovators developing new therapies.”
CMTP also recently held an in-person Stakeholder Advisory Board meeting on the Comparison of Operative to Monitoring and Endocrine Therapy for Low Risk DCIS (COMET) study. The study is enrolling women with low-risk ductal carcinoma in situ for a phase III randomized trial.
For more information on the COMET study, click here.